Cabot Wealth Management Inc. Buys 1,569 Shares of Eli Lilly and Company $LLY

Cabot Wealth Management Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 10.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,987 shares of the company’s stock after purchasing an additional 1,569 shares during the quarter. Eli Lilly and Company makes up about 1.7% of Cabot Wealth Management Inc.’s investment portfolio, making the stock its 16th largest holding. Cabot Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $18,498,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of LLY. Pavion Blue Capital LLC grew its stake in shares of Eli Lilly and Company by 0.6% in the third quarter. Pavion Blue Capital LLC now owns 1,815 shares of the company’s stock worth $2,100,000 after acquiring an additional 10 shares during the last quarter. Advisor Resource Council increased its holdings in shares of Eli Lilly and Company by 17.2% during the third quarter. Advisor Resource Council now owns 478 shares of the company’s stock valued at $546,000 after acquiring an additional 70 shares in the last quarter. Ritholtz Wealth Management increased its holdings in shares of Eli Lilly and Company by 3.7% during the third quarter. Ritholtz Wealth Management now owns 23,254 shares of the company’s stock valued at $26,906,000 after acquiring an additional 834 shares in the last quarter. Granville Capital Inc. boosted its stake in Eli Lilly and Company by 4.8% in the 3rd quarter. Granville Capital Inc. now owns 960 shares of the company’s stock worth $1,111,000 after purchasing an additional 44 shares in the last quarter. Finally, Jacobi Capital Management LLC boosted its stake in Eli Lilly and Company by 1.6% in the 3rd quarter. Jacobi Capital Management LLC now owns 14,403 shares of the company’s stock worth $16,665,000 after purchasing an additional 223 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,437.46 on Thursday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00. The company has a market cap of $1.35 trillion, a P/E ratio of 46.66, a price-to-earnings-growth ratio of 1.72 and a beta of 0.40. The stock’s fifty day moving average price is $1,231.13 and its 200-day moving average price is $1,106.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the prior year, the business earned $7.02 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 38.6% compared to the same quarter last year. On average, equities analysts forecast that Eli Lilly and Company will post 35.67 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 22.46%.

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Citigroup increased their price objective on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Truist Financial reiterated a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Finally, TD Cowen reissued a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,416.64.

More Eli Lilly and Company News

These are some of the LLY news items that stood out recently:

• Positive Sentiment: Foundayo, Lilly’s GLP-1 weight-loss pill, was reported to have shown substantial improvement in sleep apnea, adding to the potential uses of the company’s obesity pipeline. Article: Foundayo and sleep apnea
• Positive Sentiment: A recent report says Lilly raised its 2026 sales outlook to as much as $92 billion, reinforcing expectations that strong demand for its obesity and diabetes medicines can drive continued growth. Article: Lilly’s 2026 sales outlook
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add a warning about rare NAION-related vision loss. Zepbound is among the medicines affected, creating a potential safety concern for Lilly’s key product category. Article: FDA warning on GLP-1 drugs

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.